- Home
- GEG vs LUNG Comparison
GEG vs LUNG Comparison
Compare GEG & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- LUNG
- Stock Information
- Founded
- GEG 1994
- LUNG 1995
- Country
- GEG United States
- LUNG United States
- Employees
- GEG N/A
- LUNG N/A
- Industry
- GEG Computer Software: Prepackaged Software
- LUNG Industrial Specialties
- Sector
- GEG Technology
- LUNG Health Care
- Exchange
- GEG Nasdaq
- LUNG Nasdaq
- Market Cap
- GEG 72.4M
- LUNG 65.6M
- IPO Year
- GEG N/A
- LUNG 2020
- Fundamental
- Price
- GEG $2.80
- LUNG $1.60
- Analyst Decision
- GEG
- LUNG Buy
- Analyst Count
- GEG 0
- LUNG 7
- Target Price
- GEG N/A
- LUNG $7.66
- AVG Volume (30 Days)
- GEG 902.9K
- LUNG 467.3K
- Earning Date
- GEG 11-10-2025
- LUNG 10-29-2025
- Dividend Yield
- GEG N/A
- LUNG N/A
- EPS Growth
- GEG N/A
- LUNG N/A
- EPS
- GEG 0.38
- LUNG N/A
- Revenue
- GEG $16,315,999.00
- LUNG $90,549,000.00
- Revenue This Year
- GEG N/A
- LUNG $10.30
- Revenue Next Year
- GEG N/A
- LUNG $14.72
- P/E Ratio
- GEG $7.47
- LUNG N/A
- Revenue Growth
- GEG N/A
- LUNG 18.24
- 52 Week Low
- GEG $1.70
- LUNG $1.47
- 52 Week High
- GEG $3.51
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- GEG 58.00
- LUNG 40.86
- Support Level
- GEG $2.58
- LUNG $1.54
- Resistance Level
- GEG $2.99
- LUNG $1.63
- Average True Range (ATR)
- GEG 0.25
- LUNG 0.12
- MACD
- GEG -0.01
- LUNG 0.02
- Stochastic Oscillator
- GEG 42.28
- LUNG 19.35
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.